A previous study demonstrated that the MMR status can predict the clinical benefit of ICB across 12 tumour types5, making ICB the first Food and Drug Administration-approved tissue-agnostic therapy for MSI-H cancers34. The gene discussed is MRC1; the disease is neoplasm.